Other risk factors for ANV include, but are not limited to, female sex, previous ANV, history of motion sickness, and morning sickness during pregnancy. Prevention strategies include behavior therapies, acupuncture, and administration of anxiolytic
Search Results
Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Smita Bhatia, Alberto S. Pappo, Melissa Acquazzino, Wendy A. Allen-Rhoades, Marie Barnett, Scott C. Borinstein, Robert Casey, Sun Choo, Rashmi Chugh, Shira Dinner, Ralph Ermoian, Douglas Fair, Noah Federman, Jeanelle Folbrecht, Shipra Gandhi, Julie Germann, Robert Goldsby, Robert Hayashi, Alex Y. Huang, Mary S. Huang, Linda A. Jacobs, Cathy Lee-Miller, Michael P. Link, John A. Livingston, Maryam Lustberg, Marcio Malogolowkin, Kevin C. Oeffinger, Christine A. Pratilas, Damon Reed, Jodi Skiles, Margaret von Mehren, Nicholas Yeager, Sarah Montgomery, and Lisa Hang
Treatment Strategies for Myeloid Growth Factors and Intravenous Iron: When, What, and How?
Jeffrey Crawford and George M. Rodgers
resistant bacteria, and do not impact the depth and duration of neutropenia, which is the major risk factor for FN. Risk Assessment Per NCCN Guidelines Before the start of chemotherapy, patients should be evaluated for their risk of FN based on
Venous Thromboembolic Disease
Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Tanya Siddiqi, Judy L. Smith, Gary C. Yee, Anaadriana Zakarija, Nicole McMillian, and Maoko Naganuma
damage, and stasis from direct vascular compression. 6 - 8 The incidence of cancer-associated VTE is further increased by the presence of additional risk factors, such as acquired or congenital thrombophilia (eg, antiphospholipid syndrome, factor V
Management of Patients With Aggressive Nonmelanoma Skin Cancers
Presented by: Valencia D. Thomas, Michael K. Wong, and Andrew J. Bishop
, provide an outline for patient stratification based on risk factors for local recurrence, metastases, and death from disease ( Figure 1 ). 2 “There are so many characteristics and elements that we must take into consideration that there are conflicting
Hepatocellular Carcinoma: Updates to Screening and Diagnosis
Anne M. Covey
have a known risk factor, 11 and we believe that implementing screening programs for those known populations improves OS. Other risk factors in the setting of HCV cirrhosis include male sex, coinfection with HIV or HBV, older age, diabetes, and obesity
Preventive Health in Cancer Survivors: What Should We Be Recommending?
Linda S. Overholser and Carlin Callaway
cause of death for adults in the US general population, is now known to be a leading cause of death in individuals treated for cancer. 7 – 12 As with cancer, CVD in survivors could be due to common behavioral risk factors, a family history, a late
The Impact of Adjuvant Chemotherapy on the Long-Term Prognosis of Breast Malignant Phyllodes Tumors: A Propensity Score–Matched Study
Zilin Zhuang, Ailifeire Yilihamu, Zhihua Li, Rong Lei, Xun Li, Mengjia Han, Wei Wei, Guangxin Li, Zhen Ma, Yulu Zhang, Hui Hu, Xiaoyun Xiao, and Yan Nie
months. 3 , 9 – 12 Due to the rarity and aggressive clinical nature of MPTs, effective treatment options for local recurrence and distant metastases following surgery remain elusive. This underscores the importance of assessing predictive risk factors
What’s in a Number? Examining the Prognostic and Predictive Importance of Platelet Count in Patients With Essential Thrombocythemia
Andrew T. Kuykendall and Rami Komrokji
corresponding risk category being assigned. 2 – 4 Additional risk factors have been proposed but not universally incorporated into risk-stratification models, including cardiovascular risk factors, leukocytosis, and, perhaps most controversially, platelet count
Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Nadeem R. Abu-Rustum, Catheryn M. Yashar, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Susana M. Campos, Junzo Chino, Hye Sook Chon, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Stephanie Gaillard, Robert Giuntoli II, Scott Glaser, Jordan Holmes, Brooke E. Howitt, Kari Kendra, Jayanthi Lea, Nita Lee, Gina Mantia-Smaldone, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Mirna Podoll, Kerry Rodabaugh, Ritu Salani, John Schorge, Jean Siedel, Rachel Sisodia, Pamela Soliman, Stefanie Ueda, Renata Urban, Stephanie L. Wethington, Emily Wyse, Kristine Zanotti, Nicole McMillian, and Sara Espinosa
(SLN) biopsy or ipsilateral IF lymphadenectomy; the latter should be performed if no SLN(s) is/are detected. Adjuvant therapy is informed by primary tumor risk factors and nodal surgical pathology. Patients with anterior or posterior central vulvar
Prevention and Treatment of Cancer-Related Infections
Lindsey Robert Baden, William Bensinger, Michael Angarone, Corey Casper, Erik R. Dubberke, Alison G. Freifeld, Ramiro Garzon, John N. Greene, John P. Greer, James I. Ito, Judith E. Karp, Daniel R. Kaul, Earl King, Emily Mackler, Kieren A. Marr, Jose G. Montoya, Ashley Morris-Engemann, Peter G. Pappas, Ken Rolston, Brahm Segal, Susan K. Seo, Sankar Swaminathan, Maoko Naganuma, and Dorothy A. Shead
risk factor for the development of infections in patients undergoing chemotherapy. Effective strategies to anticipate, prevent, and manage infectious complications in neutropenic patients with cancer have led to improved outcomes. 1 – 12 Because of
